stem cell retraction, page-10

I see from the quarterlies that TIS pays QUT for R&D. Hard to say what that is about but it makes sense given that QUT developed VG in the first place and then licensed TIS (I don't know the details either) to commercialise it.

I haven't found any mention of TIS paying for QUT employees to attend conferences and seminars OS and I'm not sure that could be written off as a R&D expense.

Also of note is the fact that QUT is the second largest shareholder of TIS.

DYOR

Rev